← Back to Clinical Trials
Recruiting NCT02836262

NCT02836262 Hip Replacement System (HRS-P) in Primary Total Hip Arthroplasty

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02836262
Status Recruiting
Phase
Sponsor Hip Innovation Technology
Condition Osteoarthritis of Hip
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2017-08-25
Primary Completion 2025-08-25

Trial Parameters

Condition Osteoarthritis of Hip
Sponsor Hip Innovation Technology
Study Type INTERVENTIONAL
Phase N/A
Enrollment 100
Sex ALL
Min Age 65 Years
Max Age 79 Years
Start Date 2017-08-25
Completion 2025-08-25
Interventions
HIT Hip Replacement System

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

To evaluate effectiveness and safety of HHRS in subjects undergoing total hip arthroplasty (THA). Effectiveness will be evaluated using patient-reported, clinical, radiologic, and radiostereometric outcomes. Safety will be evaluated through the collection of device-related and unanticipated device-related adverse events.

Eligibility Criteria

Inclusion Criteria: * Patient has a non-inflammatory degenerative joint disease (NIDJD) or any of its composite diagnoses such as osteoarthritis, avascular necrosis, traumatic arthritis, slipped capital epiphysis, fracture of the pelvis, and diastrophic variant requiring unilateral primary total hip replacement. * Age between 65 and 79 years (inclusive) at the time of enrollment. * Patient is a suitable candidate for primary total hip replacement at the discretion of the Investigator. * Pre-surgery (within 28 days before surgery) WOMAC Global Score of 40 or larger on a scale from 0 (best) to 96 (worst) * Signed and dated informed consent document. * Patient is willing and able to participate in required follow-up visits at the Investigational site and to complete study procedures and questionnaires. Exclusion Criteria: * Patient has had total hip replacement, hemi-arthroplasty, or fusion in either hip in the last 12 months; * Patient has planned total hip arthroplasty on a contra-later

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology